Advertisement

Advertisement
Lung Cancer
Immunotherapy

Neoadjuvant Atezolizumab Plus Chemotherapy for Resectable NSCLC

In a phase II study reported in The Lancet Oncology, Shu et al found that neoadjuvant treatment with atezolizumab plus nab-paclitaxel...

COVID-19

ASCO Coronavirus Resources

As the coronavirus (COVID-19) continues to spread, ASCO is committed to providing the most current information and resources to its members and the larger oncology...

COVID-19

COVID-19 Infection in Pediatric Patients With Cancer

In a study reported in a research letter in JAMA Oncology, Boulad et al found a low rate of COVID-19 morbidity among infected pediatric patients...


Advertisement
Issues in Oncology
Pain Management

Opioid-Related Deaths in the Cancer Population vs the General Population

In a study reported in a research letter in JAMA OncologyFumiko Chino, MD, and colleagues found that while the incidence...

COVID-19

Lessons Learned on Rotation at COVID-19 Inpatient Service at New York City Hospital

I am happy to report I have just completed a 7-day rotation at the COVID-19 inpatient service at my hospital in New York City...

Advertisement



Sponsored Content


Supportive Care

Christopher D'Avella, MD, on Utilizing a Specialized Urgent Care Center for Patients With Cancer

Gastrointestinal Cancer
Lung Cancer
Leukemia
Hepatobiliary Cancer
Kidney Cancer
Immunotherapy

FDA Pipeline: Two Breakthrough Therapy Designations for Fam-Trastuzumab Deruxtecan-nxki, and More

Over the past few weeks, the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designations for an antibody-drug conjugate in the treatment of gastric and lung cancers. The Agency has also issued Orphan Drug designations for agents being investigated in chronic myeloid...

Advertisement

Impact of Genes on Total Number and Type of Nevi

A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer.  “The goal was to investigate the genetic underpinnings of different mole classes, or...

Leukemia
COVID-19

Laura C. Michaelis, MD: In My Experience Question 5

Gynecologic Cancers

SGO 2020: Wee1 Inhibition in Recurrent Uterine Serous Carcinoma

In a clinical trial in patients with recurrent uterine serous carcinoma, one-third of study participants responded to treatment with the Wee1 inhibitor adavosertib, according to data presented by Liu et al at a virtual session of the Society for Gynecologic Oncology (SGO) Annual Meeting on Women’s...

Hematologic Malignancies
Symptom Management

Ruxolitinib in Glucocorticoid-Refractory Acute Graft-vs-Host Disease After Stem Cell Transplant

In the phase III REACH2 trial reported in The New England Journal of Medicine, Zeiser et al found that the JAK1/2 inhibitor ruxolitinib improved response rate vs investigator’s choice of therapy in patients with glucocorticoid-refractory acute graft-vs-host disease (GVHD) following allogeneic stem...

Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma

In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...

Hematologic Malignancies
COVID-19

William A. Wood, MD, MPH, on the New ASH Research Collaborative Data Hub COVID-19 Registry for Hematologic Malignancy

Sarcoma

FDA Approves Pomalidomide for Kaposi Sarcoma

On May 14, 2020, the U.S. Food and Drug Administration (FDA) expanded the indication of pomalidomide (Pomalyst) to include treating adult patients with acquired immunodeficiency syndrome (AIDS)-related Kaposi sarcoma after failure of highly active antiretroviral therapy and those with Kaposi...

Advertisement

Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...